摘要
目的:探讨反义BCR和ABL融合基因(BCR/ABL融合基因)寡核苷酸体外抑制K562细胞的作用及机制。方法:采用K562细胞培养,观察反义BCR/ABL寡核苷酸体外对K562细胞数、台盼蓝拒染率及克隆形成等的影响。结果:经反义BCR/ABL寡核苷酸b3a2(ASb3a2)处理后培养8d的K562克隆抑制率达6069%,液体培养中细胞数从24h开始较对照组减少,细胞存活率从8h开始即较对照组明显下降,BCR/ABL寡核苷酸b2a2(ASb2a2)及无义寡核苷酸对K562细胞数和存活率无明显影响;3种寡核苷酸对HL60细胞数和存活率也无影响。结论:ASb3a2对K562细胞有序列特异性的抑制作用。ASb3a2的这种抑制作用可能在于它诱导K562细胞的凋亡。
Objective: To explore the inhibition of K562 cell lines by bcr abl antisense oligonucleotide in vitro. Methods: K562 cell line was used to observe the influences on cell proliferation, the ability to exclude trypan blue and the clonal formation in vitro treatment with BCR/ABL antisense oligonucleotide. Results: The clonal formation of K562 cell line after treatment with BCR/ABL antisense oligonucleotide b3a2 (AS b3a2) was inhibited obviously. In liquid culture, the quantity of cell proliferation decreased from 24 hour after treatment, while the ability to exclude trypan blue significantly decreased from 8 hours after treatment. No influences on the number and activities of K562 cells were found when the cells were treated with BCR/ABL antisense oligonucleotide b2a2 (AS b2a2) or non sense oligonucleotide. Meanwhile, these three oligonucleotides could not influence the number and activities of HL 60 cell lines. Conclusions: AS b3a2 could sequence specifically inhibit activities and proliferation of K562 cells.
出处
《中山医科大学学报》
CSCD
1999年第1期53-55,72,共4页
Academic Journal of Sun Yat-sen University of Medical Sciences
关键词
白血病
CML
药物疗法
基因治疗
寡核苷酸
leukemia, myeloid, chronic/drug therapy
apoptosis/drug effects
gene, abl
oligonucleotide, antisense/therapeutic use
tumor cells, cultured